Eli Lilly and Co. (NYSE:LLY) on Monday announced positive results from its Phase 3 ADorable-1 trial for Ebglyss (lebrikizumab-lbkz) in pediatric patients with moderate-to-severe atopic dermatitis.

Atopic dermatitis is more common in children than adults, affecting 9.6 million children in the U.S., one-third of whom have moderate-to-severe disease.

Lilly plans to submit these data to the U.S. and global regulators for a potential label update.

Eli Lilly Trial Met Primary And Secondary Endpoints

Ebglyss met the primary and key secondary endpoints at Week 16, improving disease severity while delivering skin clearance and relief from persistent itch.

In the ADorable-1 study, 63% of patients achieved significant skin improvement, while 44% reached clear or almost clear skin at Week 16. Additionally, 39% of participants achieved near-complete skin clearance, and 35% experienced significant itch relief.

Safety Profile Consistent With Earlier Studies

The safety profile of EBGLYSS was consistent with previous studies, with no new safety signals observed.

The ADorable clinical program is ...